Skip to main content

Year: 2025

ParaZero’s DropAir Achieves Life-Saving Breakthrough in Precision Critical Blood Transfusions Delivery with IDF and Israeli Ministry of Defense

Kfar Saba, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced the successful completion of a joint field trial of its DropAir system for the precision delivery of blood units. The trial was conducted in collaboration with MAFAT (the Israeli Ministry of Defense Directorate of Defense R&D), the Israeli Ministry of Health, and the Israel Defense Forces (IDF), including the Medical Corps and Technology & Logistics Directorate (ATAL). During the trial, blood Transfusions were dropped from an altitude of 200 meters AGL using ParaZero’s DropAir system. Following recovery, the Transfusions were inspected by doctors...

Continue reading

VCI Global Expands Platform Strategy with Smart Bridge Launch into US$16 Trillion Real-World Asset Tokenization Market

New RWA Consultancy Expected to Diversify Revenues, Enhance Margins, and Strengthen VCIG’s Cross-Sector Growth Sector KUALA LUMPUR, Malaysia, Sept. 09, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), today announced that its subsidiary, Smart Bridge Technologies Limited (“Smart Bridge”), has launched a dedicated Real-World Asset (RWA) consultancy to capture share in the US$16 trillion tokenization market projected by Boston Consulting Group and ADDX. The launch marks a strategic expansion of VCI Global’s cross-sector platform, which integrates capital markets consultancy, AI, fintech, and cybersecurity. With Smart Bridge, the Company is extending its reach into the fast-growing tokenization space, unlocking opportunities where traditional finance and digital assets converge. Smart Bridge...

Continue reading

FG Nexus Announces $200 Million Share Repurchase Program

Charlotte, NC, Sept. 09, 2025 (GLOBE NEWSWIRE) — FG Nexus Inc. (Nasdaq: FGNX, FGNXP) (the “Company”), today announced that its Board of Directors has approved a Share repurchase program to acquire up to $200 million of the Company’s outstanding common stock (the “Share Repurchase Program”). The Stock Repurchase Program, which is open-ended, allows the Company to repurchase its shares from time to time in the open market and in negotiated transactions. Any repurchases conducted pursuant to the Share Repurchase Program will be in accordance with Rule 10b-18 of the Exchange Act and will be made in accordance with applicable laws and regulations in effect from time to time. “The Share Repurchase Program reflects our confidence in FG Nexus’s long-term prospects and our commitment to delivering value to shareholders”...

Continue reading

Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testing IBS affects an estimated 40 million adults in the U.S. and hundreds of millions worldwideIRVINE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic and therapeutic solutions, today announced the launch of its inFoods® IBS Trigger Food Navigator, a comprehensive AI-backed digital companion tool designed to better enable patient dietary compliance and improve treatment success for individuals with Irritable Bowel Syndrome (IBS). The inFoods® IBS test identifies, on average, two to four specific foods that trigger a patient’s IBS symptoms, leading to a simple, highly targeted and actionable dietary plan. The new AI-backed Trigger...

Continue reading

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue an Accelerated Approval with the U.S. Food and Drug Administration for Iopofosine I 131 as a Treatment for WM Advancing Auger-Emitting Radiopharmaceutical Product Candidate into Phase 1b Clinical Trial for the Treatment of Triple-Negative Breast Cancer in 4Q25 FLORHAM PARK, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Company management will participate at the upcoming Oppenheimer 3rd Annual Targeted...

Continue reading

24/7 Market News TEN Holdings Supercharges Growth with SaaS and Synergies

Customer Boom and M&A on Deck DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that TEN Holdings (NASDAQ: XHLD), a provider of event planning, production, and broadcasting services through its operating subsidiary Ten Events, is demonstrating robust execution and accelerating growth, according to a recent update from All-Star Analyst Barry M. Sine, CFA, CMT. Sine, a two-time Wall Street Journal and Financial Times All-Star Analyst, reiterated his full-year revenue estimate, highlighting TEN Holdings’ strong customer traction, ahead-of-schedule progress on its Ten Events Pro (“Ten Pro”) SaaS platform, and promising merger and acquisition (M&A) opportunities. The report highlights accelerating...

Continue reading

24/7 Market News: Ken Le, Not Stan Lee, to Lead Prodigy Silk’s Super Fiber Deliveries to Global Brands for Kraig Labs

DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, analyses Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, appointment of Kenneth Le as Managing Director of Prodigy Silk Ltd, the Company’s wholly owned recombinant spider silk production subsidiary in Southeast Asia. The strategic promotion of Le comes at a pivotal moment. With the Company now preparing to kick off its revamped spider silk production model and focus on its first sample deliveries to three high-profile global clients, Le’s leadership is expected to catalyze the transition from production scale-up to commercial super fiber deployment. Operational Excellence for a Next-Gen...

Continue reading

Cuprina Secures Exclusive Rights to Southeast Asia’s First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology

SINGAPORE, Sept. 09, 2025 (GLOBE NEWSWIRE) — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it has secured exclusive licensing rights to Southeast Asia’s first medical waste recycling technology developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF), the major alliance supporting developing countries in achieving global environmental benefits.  The license, signed by Cuprina with China-based Zhejiang Heliang Technology Co., Ltd., covers Singapore and an option to expand into ten additional...

Continue reading

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control. Approximately $16.9 million paid to acquire 65% equity stake in recapitalized debt-free NKMax, with NKMax operations now expected to be funded through 2026. Funding provided by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y. Song.SANTA ANA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the successful completion of its acquisition of a majority equity stake in NKMax Co., Ltd. (“NKMax”),...

Continue reading

Fancamp Reports Results of Prospecting and Soil Geochemical Survey at New Brunswick Acadian Gold and Announces Imminent Drill Program

VANCOUVER, British Columbia, Sept. 09, 2025 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Company”) (TSX Venture Exchange: FNC) is pleased to announce prospecting and soil geochemical exploration results of an exploration program conducted by Acadian Gold, a joint venture with Lode Gold Resources Inc. for the advancement of a district scale, 445 km² land package located in a highly prospective region for gold and polymetallic mineral discovery, in northern New Brunswick. Acadian Gold is one of the largest under-explored holdings in this emerging gold camp, with two key properties; McIntyre Brook, adjacent to Puma Exploration’s Williams Brook Project (which holds an option agreement with Kinross Gold), and Riley Brook, a significantly sized property surrounded by recent claims acquisitions made by Kenorland Minerals....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.